Nektar Therapeutics Gestion

Gestion contrôle des critères 3/4

Le PDG Nektar Therapeutics est Howard Robin, nommé en Jan2007, a un mandat de 17.83 ans. La rémunération annuelle totale est $ 3.14M, composée du salaire de 34.6% et des bonus 65.4%, y compris les actions et options de la société. détient directement 0.39% des actions de la société, d'une valeur de $ 755.30K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5.8 ans et 16.3 ans.

Informations clés

Howard Robin

Directeur général

US$3.1m

Rémunération totale

Pourcentage du salaire du PDG	34.6%
Durée du mandat du directeur général	17.8yrs
Propriété du PDG	0.4%
Durée moyenne d'occupation des postes de direction	5.8yrs
Durée moyenne du mandat des membres du conseil d'administration	16.3yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Howard Robin a-t-elle évolué par rapport aux bénéfices de Nektar Therapeutics?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-US$168m
Jun 30 2024	n/a	n/a	-US$177m
Mar 31 2024	n/a	n/a	-US$176m
Dec 31 2023	US$3m	US$1m	-US$276m
Sep 30 2023	n/a	n/a	-US$294m
Jun 30 2023	n/a	n/a	-US$307m
Mar 31 2023	n/a	n/a	-US$415m
Dec 31 2022	US$11m	US$1m	-US$368m
Sep 30 2022	n/a	n/a	-US$454m
Jun 30 2022	n/a	n/a	-US$525m
Mar 31 2022	n/a	n/a	-US$491m
Dec 31 2021	US$11m	US$1m	-US$524m
Sep 30 2021	n/a	n/a	-US$495m
Jun 30 2021	n/a	n/a	-US$474m
Mar 31 2021	n/a	n/a	-US$429m
Dec 31 2020	US$11m	US$1m	-US$444m
Sep 30 2020	n/a	n/a	-US$439m
Jun 30 2020	n/a	n/a	-US$429m
Mar 31 2020	n/a	n/a	-US$460m
Dec 31 2019	US$10m	US$1m	-US$441m
Sep 30 2019	n/a	n/a	-US$427m
Jun 30 2019	n/a	n/a	-US$424m
Mar 31 2019	n/a	n/a	US$657m
Dec 31 2018	US$13m	US$969k	US$681m
Sep 30 2018	n/a	n/a	US$746m
Jun 30 2018	n/a	n/a	US$903m
Mar 31 2018	n/a	n/a	-US$129m
Dec 31 2017	US$18m	US$941k	-US$97m

Rémunération vs marché: La rémunération totale de Howard ($USD 3.14M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché UK ($USD 739.97K ).

Rémunération et revenus: La rémunération de Howard a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Howard Robin (71 yo)

17.8yrs

Titularisation

US$3,135,576

Compensation

Mr. Howard W. Robin has been the Chief Executive Officer and the President of Prime Holdings & Investments Inc. since July 2001. Mr. Robin has been the Chief Executive Officer and President of Nektar Thera...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Howard Robin	CEO, President & Director	17.8yrs	US$3.14m	0.39% $ 755.3k
Sandra Gardiner	Chief Financial Officer	1.6yrs	US$376.30k	pas de données
Mark Wilson	Senior VP	8.3yrs	US$1.10m	0.12% $ 229.8k
Jonathan Zalevsky	Chief Research & Development Officer	5.1yrs	US$1.77m	0.13% $ 255.2k
Vivian Wu	Director of Investor Relations & Corporate Affairs	no data	pas de données	pas de données
Robert Bacci	Senior Vice President of Human Resources & Facilities Operations	2.9yrs	pas de données	pas de données
Jennifer Ruddock	Chief Business Officer	5.8yrs	pas de données	pas de données
Mary Tagliaferri	Chief Medical Officer	7yrs	pas de données	pas de données

5.8yrs

Durée moyenne de l'emploi

58yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de 0UNL est chevronnée et expérimentée (5.8 années d'ancienneté moyenne).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Howard Robin	CEO, President & Director	17.8yrs	US$3.14m	0.39% $ 755.3k
Robert Chess	Independent Chairman of the Board	32.5yrs	US$176.22k	0.14% $ 274.7k
R. Greer	Independent Director	14.8yrs	US$170.22k	0.16% $ 318.8k
Roy Whitfield	Lead Independent Director	24.3yrs	US$170.22k	0.16% $ 302.1k
Jeffrey Ajer	Independent Director	7.2yrs	US$134.22k	0.019% $ 35.9k
Diana Brainard	Independent Director	3yrs	US$112.72k	0.012% $ 23.6k

16.3yrs

Durée moyenne de l'emploi

66.5yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la 0UNL est chevronné et expérimenté ( 16.3 années d'ancienneté moyenne).

Nektar Therapeutics Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Nektar Therapeutics, Annual General Meeting, Jun 05, 2024

CEO, President & Director recently sold US$59k worth of stock

Insufficient new directors

CEO, President & Director recently sold US$136k worth of stock

CEO, President & Director recently sold US$65k worth of stock

Nektar Promotes Jillian B. Thomsen to Senior Vice President

Recent updates

Nektar Therapeutics Provides Earnings Guidance for the Full Year of 2024

Third quarter 2024 earnings released: US$0.18 loss per share (vs US$0.24 loss in 3Q 2023)

Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Ampersand Management LLC entered into an Asset Purchase Agreement to acquire Manufacturing Facility and Reagent Supply Business in Huntsville, Alabama of Nektar Therapeutics from Nektar Therapeutics (NasdaqCM:NKTR) for $90 million.

Ampersand Management LLC entered into an Asset Purchase Agreement to acquire Manufacturing Facility and Reagent Supply Business in Huntsville, Alabama of Nektar Therapeutics from Nektar Therapeutics (NasdaqCM:NKTR) for $90 million.

New major risk - Revenue and earnings growth

Nektar Therapeutics to Report Q3, 2024 Results on Nov 07, 2024

Nektar Therapeutics Announces Publication in Nature Communications of Results from Phase 1B Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases

Nektar Therapeutics Announces Publication in Blood of Phase 1 Data for Novel II-15 Agonist NKTR-255 in Combination with Autologous CD19-22 Car-T Cell Therapy in Patients with B-Cell Acute Lymphoblastic Leukemia

Second quarter 2024 earnings released: US$0.25 loss per share (vs US$0.27 loss in 2Q 2023)

Nektar Therapeutics to Report Q2, 2024 Results on Aug 08, 2024

First quarter 2024 earnings released: US$0.19 loss per share (vs US$0.72 loss in 1Q 2023)

Nektar Therapeutics to Report Q1, 2024 Results on May 09, 2024

Nektar Therapeutics, Annual General Meeting, Jun 05, 2024

Nektar Therapeutics announced that it has received $30 million in funding from TCG Crossover Management, LLC

Full year 2023 earnings released: US$1.45 loss per share (vs US$1.97 loss in FY 2022)

Nektar Therapeutics Announces Initiation of Phase 2B Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata

Nektar Therapeutics announced that it expects to receive $30 million in funding from TCG Crossover Management, LLC

Nektar Therapeutics to Report Q4, 2023 Results on Mar 04, 2024

New major risk - Share price stability

Nasdaq States Nektar Therapeutics Eligible for an Additional 180 Calendar Day Period, or Until May 20, 2024, to Regain Compliance with the Minimum Bid Price Requirement

Nasdaq States Nektar Therapeutics Eligible for an Additional 180 Calendar Day Period, or Until May 20, 2024, to Regain Compliance with the Minimum Bid Price Requirement

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.32 loss in 3Q 2022)

Nektar Therapeutics to Report Q3, 2023 Results on Nov 07, 2023

Nektar Therapeutics Presents New Responder Data for Rezpegaldesleukin, A First-In-Class Selective Regulatory T-Cell Therapy

New minor risk - Market cap size

Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate Nktr-255 in Combination with C-Til051 in Advanced Non-Small Cell Lung Cancer

Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-To-Severe Atopic Dermatitis

Second quarter 2023 earnings released: US$0.27 loss per share (vs US$0.85 loss in 2Q 2022)

Nektar Therapeutics Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company

Nektar Therapeutics to Report Q2, 2023 Results on Aug 08, 2023

New minor risk - Market cap size

Nektar Therapeutics(NasdaqGS:NKTR) dropped from Russell 2000 Index

New minor risk - Market cap size

Nektar Therapeutics Receives Notice from The Nasdaq Global Select Market Due to Non-Compliance with the Minimum Bid Price Rule

First quarter 2023 earnings released: US$0.72 loss per share (vs US$0.49 loss in 1Q 2022)

Nektar Therapeutics Reports Impairment of Goodwill for the First Quarter Ended March 31, 2023

Full year 2022 earnings released: US$1.97 loss per share (vs US$2.86 loss in FY 2021)

CEO, President & Director recently sold US$59k worth of stock

Insufficient new directors

CEO, President & Director recently sold US$136k worth of stock

Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, A Novel Polymer-Conjugated Human IL-15, Improves Efficacy of CD19-Targeted CAR-T Cell Immunotherapy

Third quarter 2022 earnings released: US$0.32 loss per share (vs US$0.70 loss in 3Q 2021)

Nektar Therapeutics to Report Q3, 2022 Results on Nov 03, 2022

Nektar Therapeutics (NasdaqGS:NKTR) submitted a non-binding proposal to acquire PureTech Health plc (LSE:PRTC).

Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (Eadv) Congress

CEO, President & Director recently sold US$65k worth of stock

Nektar Therapeutics Announces Preclinical Publication of Data for NKTR-255 and Its Observed Improvement of NK Cell Function in Multiple Myeloma

Second quarter 2022 earnings released: US$0.85 loss per share (vs US$0.69 loss in 2Q 2021)

Nektar Therapeutics Provides Earnings Guidance for the Year 2022

Nektar Therapeutics to Report Q2, 2022 Results on Aug 04, 2022

Nektar Promotes Jillian B. Thomsen to Senior Vice President

Nektar Therapeutics(NasdaqGS:NKTR) dropped from Russell 1000 Dynamic Index

Nektar Therapeutics Reviews Interim Efficacy and Safety Data from the Ongoing Phase 2 Double Blinded, Placebo-Controlled Study

CEO, President & Director recently sold US$144k worth of stock

First quarter 2022 earnings released: US$0.49 loss per share (vs US$0.68 loss in 1Q 2021)

Nektar Therapeutics, Annual General Meeting, Jun 08, 2022

John Northcott Step Down as Senior Vice President and Chief Commercial Officer of Nektar Therapeutics

Nektar Therapeutics and Bristol-Myers Squibb Company Announce Update on Clinical Development Program for Bempegaldesleukin (Bempeg) in Combination with Opdivo (Nivolumab)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Nektar Therapeutics Provides Revenue Guidance for the Full Year 2022

Chief Research & Development Officer recently sold US$119k worth of stock

Nektar Therapeutics to Report Q4, 2021 Results on Feb 28, 2022

Nektar Therapeutics Presents Clinical Data for NKTR-255 in Patients with Relapsed/Refractory Hematologic Malignancies, Including Patients with Prior CAR-T Therapy, At the 63Rd American Society of Hematology (ASH) Annual Meeting

Nektar Therapeutics Announces Data Presentations for Its Immuno-Oncology Programs At the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2021 and the 63rd American Society of Hematology (ASH) Annual Meeting

Senior VP recently sold US$278k worth of stock

Third quarter 2021 earnings released: US$0.70 loss per share (vs US$0.61 loss in 3Q 2020)

Insider recently sold US$65k worth of stock

Redhill Biopharma Inc., AstraZeneca AB and AstraZeneca Pharmaceuticals LP and Nektar Therapeutics Enters into A Settlement and License Agreement with Aurobindo Pharma USA, Inc